Literature DB >> 21455206

Sodium iodide symporter SPECT imaging of a patient treated with oncolytic adenovirus Ad5/3-Δ24-hNIS.

Maria Rajecki, Aki Kangasmäki, Leena Laasonen, Sophie Escutenaire, Tanja Hakkarainen, Jarmo Haukka, Ari Ristimäki, Kalevi Kairemo, Lotta Kangasniemi, Timo Kiljunen, Timo Joensuu, Sari Pesonen, Akseli Hemminki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21455206      PMCID： PMC3070106          DOI： 10.1038/mt.2011.31

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  16 in total

Review 1.  Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?

Authors:  B R Dix; S J Edwards; A W Braithwaite
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors.

Authors:  Petri Nokisalmi; Sari Pesonen; Sophie Escutenaire; Merja Särkioja; Mari Raki; Vincenzo Cerullo; Leena Laasonen; Ramon Alemany; Juan Rojas; Manel Cascallo; Kilian Guse; Maria Rajecki; Lotta Kangasniemi; Elina Haavisto; Aila Karioja-Kallio; Päivi Hannuksela; Minna Oksanen; Anna Kanerva; Timo Joensuu; Laura Ahtiainen; Akseli Hemminki
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

3.  Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.

Authors:  Vincenzo Cerullo; Sari Pesonen; Iulia Diaconu; Sophie Escutenaire; Petteri T Arstila; Matteo Ugolini; Petri Nokisalmi; Mari Raki; Leena Laasonen; Merja Särkioja; Maria Rajecki; Lotta Kangasniemi; Kilian Guse; Andreas Helminen; Laura Ahtiainen; Ari Ristimäki; Anne Räisänen-Sokolowski; Elina Haavisto; Minna Oksanen; Eerika Karli; Aila Karioja-Kallio; Sirkka-Liisa Holm; Mauri Kouri; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

Review 4.  Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials.

Authors:  D Kirn
Journal:  Expert Opin Biol Ther       Date:  2001-05       Impact factor: 4.388

5.  Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours.

Authors:  Andrew Merron; Patrick Baril; Pilar Martin-Duque; Antonio de la Vieja; Lucile Tran; Arnaud Briat; Kevin J Harrington; Iain A McNeish; Georges Vassaux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-06       Impact factor: 9.236

6.  Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors.

Authors:  S Pesonen; P Nokisalmi; S Escutenaire; M Särkioja; M Raki; V Cerullo; L Kangasniemi; L Laasonen; C Ribacka; K Guse; E Haavisto; M Oksanen; M Rajecki; A Helminen; A Ristimäki; A Karioja-Kallio; E Karli; T Kantola; G Bauerschmitz; A Kanerva; T Joensuu; A Hemminki
Journal:  Gene Ther       Date:  2010-03-18       Impact factor: 5.250

7.  A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model.

Authors:  Akseli Hemminki; Anna Kanerva; Eric J Kremer; Gerd J Bauerschmitz; Bruce F Smith; Bin Liu; Minghui Wang; Renee A Desmond; Anne Keriel; Brian Barnett; Henry J Baker; Gene P Siegal; David T Curiel
Journal:  Mol Ther       Date:  2003-02       Impact factor: 11.454

8.  Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

Authors:  Anniina Koski; Lotta Kangasniemi; Sophie Escutenaire; Sari Pesonen; Vincenzo Cerullo; Iulia Diaconu; Petri Nokisalmi; Mari Raki; Maria Rajecki; Kilian Guse; Tuuli Ranki; Minna Oksanen; Sirkka-Liisa Holm; Elina Haavisto; Aila Karioja-Kallio; Leena Laasonen; Kaarina Partanen; Matteo Ugolini; Andreas Helminen; Eerika Karli; Päivi Hannuksela; Saila Pesonen; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2010-07-27       Impact factor: 11.454

9.  Genetically targeted radiotherapy for multiple myeloma.

Authors:  David Dingli; Rosa Maria Diaz; Elizabeth R Bergert; Michael K O'Connor; John C Morris; Stephen J Russell
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

10.  GENIS: gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo.

Authors:  Kenneth N Barton; Donald Tyson; Hans Stricker; Young S Lew; Gregory Heisey; Sweaty Koul; Alberto de la Zerda; Fang-Fang Yin; Hui Yan; Tavarekere N Nagaraja; Kelly Ann Randall; Guk Kim Jin; Joseph D Fenstermacher; Sissy Jhiang; Jae Ho Kim; Svend O Freytag; Stephen L Brown
Journal:  Mol Ther       Date:  2003-09       Impact factor: 11.454
View more
  10 in total

1.  A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer.

Authors:  Kenneth H Kim; Igor Dmitriev; Janis P O'Malley; Minghui Wang; Souheil Saddekni; Zhiying You; Meredith A Preuss; Raymond D Harris; Rosemarie Aurigemma; Gene P Siegal; Kurt R Zinn; David T Curiel; Ronald D Alvarez
Journal:  Clin Cancer Res       Date:  2012-04-17       Impact factor: 12.531

2.  SPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131I.

Authors:  Maria Rajecki; Mirkka Sarparanta; Tanja Hakkarainen; Mikko Tenhunen; Iulia Diaconu; Venla Kuhmonen; Kalevi Kairemo; Anna Kanerva; Anu J Airaksinen; Akseli Hemminki
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

3.  Normalisation to blood activity is required for the accurate quantification of Na/I symporter ectopic expression by SPECT/CT in individual subjects.

Authors:  Peggy Richard-Fiardo; Philippe R Franken; Audrey Lamit; Robert Marsault; Julien Guglielmi; Béatrice Cambien; Fanny Graslin; Sabine Lindenthal; Jacques Darcourt; Thierry Pourcher; Georges Vassaux
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

4.  Theranostic potential of oncolytic vaccinia virus.

Authors:  Juan J Rojas; Steve H Thorne
Journal:  Theranostics       Date:  2012-04-05       Impact factor: 11.556

5.  Positive radionuclide imaging of miRNA expression using RILES and the human sodium iodide symporter as reporter gene is feasible and supports a protective role of miRNA-23a in response to muscular atrophy.

Authors:  Viorel Simion; Julien Sobilo; Rudy Clemoncon; Sharuja Natkunarajah; Safia Ezzine; Florence Abdallah; Stephanie Lerondel; Chantal Pichon; Patrick Baril
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

Review 6.  Oncolytic viruses for cancer immunotherapy.

Authors:  Otto Hemminki; João Manuel Dos Santos; Akseli Hemminki
Journal:  J Hematol Oncol       Date:  2020-06-29       Impact factor: 17.388

7.  Cancer imaging and therapy utilizing a novel NIS-expressing adenovirus: The role of adenovirus death protein deletion.

Authors:  Matthew Glen Robertson; Benjamin Bruce Eidenschink; Eriko Iguchi; Stanislav O Zakharkin; Christopher J LaRocca; Ezequiel J Tolosa; Mark J Truty; Kari Jacobsen; Martin E Fernandez-Zapico; Julia Davydova
Journal:  Mol Ther Oncolytics       Date:  2021-03-05       Impact factor: 7.200

8.  HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy.

Authors:  H Li; H Nakashima; T D Decklever; R A Nace; S J Russell
Journal:  Cancer Gene Ther       Date:  2013-07-19       Impact factor: 5.987

Review 9.  Oncolytic immunotherapy: where are we clinically?

Authors:  Akseli Hemminki
Journal:  Scientifica (Cairo)       Date:  2014-01-16

Review 10.  The use of the NIS reporter gene for optimizing oncolytic virotherapy.

Authors:  Amber Miller; Stephen J Russell
Journal:  Expert Opin Biol Ther       Date:  2015-10-12       Impact factor: 4.388
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.